Mealey's (November 9, 2022, 2:27 PM EST) -- SEATTLE — A federal judge in Washington granted a motion to dismiss filed by a biopharmaceutical company and certain of its senior officers and directors violated federal securities laws, ruling that shareholders have failed to sufficiently plead with the requisite particularity that the defendants misrepresented the safety and efficacy of the company’s developmental drug for use as an anti-tumor drug....